The Multiplex Assays Market is projected to reach $6.24 billion by 2030, at a CAGR of 9% during the forecast period, says Meticulous Research® Multiplex assays are used for the simultaneous detection of multiple analytes. Multiplex immunoassays provide an array of information on the roles of proteins, nucleic acid, and other biomolecules in varied biological processes, thereby providing clinicians with insight into the assessment and identification of disease progression.
The growth of this market is attributed to several factors: the advantages of multiplex assays over singleplex assays, the use of multiplexing in companion diagnostics, the increasing prevalence of chronic and infectious diseases, and rising awareness about the importance of early disease diagnosis. However, the high costs of multiplex assay equipment restrain the growth of this market.
The growing need for high-throughput and automated laboratory systems and the increasing focus on personalized medicine is expected to generate growth opportunities for the players operating in this market. However, the shortage of skilled professionals and the risk of cross-reactivity are major challenges for market growth.
Here are the top 10 companies operating in the Multiplex Assays Market
Seegene, Inc. (South Korea)
Founded in 1997 and headquartered in Seoul, South Korea, Seegene, Inc. develops molecular diagnostic reagents. The company operates in two product categories: Products and Systems. The company offers multiplex assay products from both categories. It provides products such as anyplex, magicplex, and seeplex. It also develops Dual Priming Oligonucleotide (DPO), Multiple Detection Temperatures (MuDT), and Tagging Oligonucleotide Cleavage and Extension (TOCE) technologies that help to identify and differentiate multiple pathogens in single reactions using real-time PCR methods.
Seegene, Inc. offers its products to end users, including physicians and clinics, technicians and clinical labs, and life science researchers. The company has a geographic presence in the U.S., Canada, South Korea, Brazil, Mexico, Italy, the Middle East, and Germany. The company has more than 100 distributors worldwide.
F. Hoffmann-La Roche AG (Switzerland)
Founded in 1896 and headquartered in Basel, Switzerland, Roche is a healthcare company that develops, manufactures, and markets a wide range of healthcare solutions. The company operates through two reportable divisions: Pharmaceuticals and Diagnostics, of which the Diagnostics division operates in the multiplex assay market.
The Diagnostics division is engaged in developing a wide range of diagnostic products and solutions such as in vitro diagnostics solutions, molecular diagnostics, clinical chemistry & immunoassays, point-of-care testing, tissue diagnostics, patient self-testing, next-generation sequencing, laboratory automation and IT, and decision support solutions.
Roche has a geographic presence across the U.S., Germany, Switzerland, Japan, China, India, New Zealand, Australia, Latin America, and Africa. Furthermore, the company has 23 manufacturing sites and 29 research and development sites worldwide.
Thermo Fisher Scientific, Inc. (U.S.)
Founded in 1956 and headquartered in Massachusetts, U.S., Thermo Fisher Scientific, Inc. offers products and services in the pharmaceutical, biotechnology, agricultural, clinical, healthcare, government, and academic sectors. The company operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. The Life Sciences Solutions and Specialty Diagnostics segment offers multiplex assay products, such as instruments, protein and RNA assay kits, and accessories.
Some of the major brands of Thermo Fisher are Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, and Patheon. The company has a direct presence through its regional offices and production sites in the U.S., Mexico, Brazil, Germany, Belgium, Austria, the U.K., Italy, the Netherlands, South Africa, the UAE, India, China, Japan, Australia, and the Republic of Korea.
Illumina, Inc. (U.S.)
Incorporated in 1998 and headquartered in California, U.S., Illumina, Inc. provides sequencing- and array-based solutions for genomic and genetic analysis. The company operates through two reportable segments: Core Illumina and GRAIL. The Core Illumina segment offers a multiplex assay solution to simplify workflows and accelerate analysis.
The company has manufacturing sites and laboratories in the U.S., Singapore, and the U.K.
Illumina distributes its products globally in North America, Europe, Latin America, Asia-Pacific, and the Middle East & Africa through its distributors. Some of its subsidiaries are Illumina GmbH (Germany), Illumina Australia Pty. Ltd. (Australia), Illumina UK, Ltd. (U.K.), Illumina Italy S.r.l. (Italy), Illumina Netherlands B.V. (Netherlands) and Illumina K.K. Japan (Japan).
Qiagen N.V. (Netherlands.)
Founded in 1984 and headquartered in Venlo, Netherlands, Qiagen N.V. is one of the leading providers of sample and assay technologies for molecular diagnostics, applied testing, and academic and pharmaceutical research. The company operates in five product groups: Sample technologies, Diagnostic solutions, PCR / Nucleic acid amplification, Genomics / NGS, and Others. The company markets its products mainly to two customer groups: Molecular Diagnostics products and Life Sciences products.
The company offers multiplex assay products from the PCR / Nucleic acid amplification category and Diagnostic Solutions. PCR / Nucleic acid amplification product category consists of Research PCR consumables, Human ID / Forensics assay consumables, PCR instruments, and OEM consumables.
Some of the major subsidiaries of the company are Qiagen AB (Sweden), Qiagen AG (Sweden), Qiagen GmbH (Germany), QIAGEN LLC (U.S.), QIAGEN China (Shanghai) Co. Ltd. (China), QIAGEN Inc. (Canada), QIAGEN K.K. (Japan), and QIAGEN S.r.l. (Italy).
Meticulous Research in its latest publication on Multiplex Assays Market has predicted the growth of 9% during the forecast year 2023-2030.
Becton, Dickinson and Company (U.S.)
Founded in 1897 and headquartered in New Jersey, U.S., Becton, Dickinson and Company is a medical technology firm engaged in developing, manufacturing, and selling various medical devices, supplies, laboratory equipment, and diagnostic products. The company offers its products to healthcare institutions, life science researchers, physicians, clinics, diagnostic laboratories, and the pharmaceutical industry.
The BD Life Sciences segment comprises two organizational units: Integrated Diagnostic Solutions and Biosciences. The company operates in the multiplex assay market through both segments.
The company has manufacturing facilities outside the U.S. in Bosnia and Herzegovina, Brazil, Canada, China, Dominican Republic, France, Germany, Hungary, India, Ireland, Italy, Japan, Mexico, the Netherlands, Singapore, Spain, and the U.K. Its subsidiaries include Becton Dickinson Canada Inc., Becton Dickinson GmbH (Germany), BD Rapid Diagnostic (Suzhou) Co., Ltd. (China), Becton Dickinson Asia Limited (Hong Kong), Becton, Dickinson B.V. (Netherlands), and Becton Dickinson India Private Limited (India).
Bio-Rad Laboratories, Inc. (U.S.)
Founded in 1952 and headquartered in California, U.S., Bio-Rad Laboratories, Inc. is a distributor and manufacturer of clinical diagnostics products and life science research. The company supplies and produces various systems and products for healthcare, analytical chemistry, and life sciences research. Bio-Rad Laboratories operates through two reportable segments: Clinical Diagnostics and Life Sciences, both segments provide products for multiplex assay.
The company has a direct distribution source in over 35 countries outside the U.S., including Afghanistan, France, Hong Kong, Japan, Korea, Iceland, Germany, Australia, Spain, the Netherlands, and South Africa. Some of the major subsidiaries of the company include Bio-Rad Laboratories Pty. Limited (Australia), Bio-Rad Pacific Limited (U.S.), Bio-Rad Laboratories SAS (France), Bio-Rad Laboratories G.m.b.H. (Germany), Bio-Rad Laboratories K.K. (Japan), Bio-Rad Korea Limited (Korea), and Bio-Rad China Ltd. (Hong Kong).
DiaSorin S.p.A (Italy)
Founded in 1968 and headquartered in Saluggia, Italy, DiaSorin S.p.A. is a medical device company manufacturing immunodiagnostics and molecular diagnostics instruments, reagents, assays, and software. The company’s products cater to healthcare professionals’ diagnostic needs for diagnostic and treatment services for gastrointestinal infections, bone and mineral, endocrinology, hypertension, cancer, onco-hematology, and autoimmunity. DiaSorin’s diagnostic products are based on immunodiagnostics and molecular diagnostics technologies.
DiaSorin has a direct presence in 24 countries and an indirect presence in 93 countries through its distributors. The company has ten manufacturing facilities in Italy, the U.K., Germany, the U.S., and Canada and nine R&D centers. Some of its subsidiaries are Luminex Molecular Diagnostics Inc. (Canada), Luminex Japan Corporation Ltd. (Japan), Luminex BV (Netherlands), Luminex Trading (Shanghai) Co. Ltd. (China), and others.
PerkinElmer, Inc. (U.S.)
Founded in 1937 and headquartered in Massachusetts, U.S., PerkinElmer, Inc. is a multinational company that offers products, solutions, and services for the life sciences, diagnostics, and applied markets. It operates through two reportable business segments: Discovery & Analytical Solutions and Diagnostics. The company offers multiplex assay through both operating business segments.
The company’s manufacturing and R&D facilities are in several countries, including the U.S., China, Japan, and Germany. Furthermore, the company has a strong network of sales and marketing channels and service personnel in over 38 countries and sells its products and services in over 190 countries.
PerkinElmer sells products and services predominantly through its distributors. Some of its subsidiaries are PerkinElmer Pty. Ltd. (Australia), PerkinElmer do Brasil Ltda. (Brazil), PerkinElmer Instruments (Shanghai) Co. Ltd. (China), PerkinElmer SAS (France), PerkinElmer Technologies GmbH & Co. KG (Germany), PerkinElmer Srl (Italy), PerkinElmer (India) Pvt Ltd. (India), and PerkinElmer Sverige AB (Sweden).
Agilent Technologies, Inc. (U.S.)
Founded in 1999 and headquartered in California, U.S., Agilent Technologies, Inc. provides application-focused solutions to the life sciences, diagnostics, and applied chemical markets. The company operates through three business segments: Life Sciences and Applied Markets, Agilent CrossLab, and Diagnostics and Genomics. The Diagnostics and Genomics segment offers the multiplex assay products market.
Agilent has a presence across North America, Europe, Asia–Pacific, Latin America, and the Middle East & Africa and customers in over 110 countries through its subsidiaries and a strong distribution network. The company has research & development and manufacturing sites in California, Colorado, Delaware, Massachusetts, Texas, Vermont, Washington, Australia, China, Denmark, Germany, Italy, Japan, Malaysia, Singapore, and the U.K.
Popular Mentions – Abbott Laboratories (U.S.), Siemens Healthineers AG (Germany), Merck KGaA (Germany), Quanterix Corporation (U.S.), and others.
Authoritative Research on the Multiplex Assays Market – Global Opportunity Analysis and Industry Forecast (2023-2030)
Need more information? Meticulous Research®’s new report covers each of these companies in much more detail, providing analysis on the following:
- Recent financial performance
- Key products
- Significant company strategies
- Partnerships and acquisitions
The Comprehensive report provides global market size estimates, market share analysis, revenue numbers, and coverage of key issues and trends.